Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens.
Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens.
复制标题
利用干血斑标本建立高通量SARS-CoV-2抗体检测途径。
DOI:
10.1177/0004563220981106
复制
发表时间:
2021-03
影响因子:
2.2
通讯作者:
Jolles S
中科院分区:
文献类型:
--
作者:
Moat SJ;Zelek WM;Carne E;Ponsford MJ;Bramhall K;Jones S;El-Shanawany T;Wise MP;Thomas A;George C;Fegan C;Steven R;Webb R;Weeks I;Morgan BP;Jolles S
Serological assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have roles in seroepidemiology, convalescent plasma-testing, antibody durability and vaccine studies. Currently, SARS-CoV-2 serology is performed using serum/plasma collected by venepuncture. Dried blood spot (DBS) testing offers significant advantages as it is minimally invasive, avoids venepuncture with specimens being mailed to the laboratory. A pathway utilizing a newborn screening laboratory infrastructure was developed using an enzyme-linked immunosorbent assay to detect IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein in DBS specimens. Paired plasma and DBS specimens from SARS-CoV-2 antibody-positive and -negative subjects and polymerase chain reaction positive subjects were tested. DBS specimen stability, effect of blood volume and punch location were also evaluated. DBS specimens from antibody-negative (n = 85) and -positive (n = 35) subjects and polymerase chain reaction positive subjects (n = 11) had a mean (SD; range) optical density (OD) of 0.14 (0.046; 0.03–0.27), 0.98 (0.41; 0.31–1.64) and 1.12 (0.37; 0.49–1.54), respectively. An action value OD >0.28 correctly assigned all cases. The weighted Deming regression for comparison of the DBS and the plasma assay yielded: y = 0.004041 + 1.005x, r = 0.991, Sy/x 0.171, n = 82. Extraction efficiency of antibodies from DBS specimens was >99%. DBS specimens were stable for at least 28 days at ambient room temperature and humidity. SARS-CoV-2 IgG receptor-binding domain antibodies can be reliably detected in DBS specimens. DBS serological testing offers lower costs than either point of care or serum/plasma assays that require patient travel, phlebotomy and hospital/clinic resources; the development of a DBS assay may be particularly important for resource poor settings.
登录
查看更多内容
影响因子:
4.2
作者:
Mei, JV;Alexander, JR;Hannon, WH
通讯作者:
Hannon, WH
影响因子:
3.7
作者:
Truong Tam Nguyen;Lemee, Veronique;Tuaillon, Edouard
通讯作者:
Tuaillon, Edouard
影响因子:
82.9
作者:
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者:
Krammer F
影响因子:
--
作者:
Stadlbauer, Daniel;Amanat, Fatima;Krammer, Florian
通讯作者:
Krammer, Florian
影响因子:
9.3
作者:
George, Roanna S.;Moat, Stuart J.
通讯作者:
Moat, Stuart J.